0308 Proxygen
BioCentury & Getty Images

Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Emerging Company Profile: Vienna’s Proxygen is taking a ligase-agnostic approach to finding molecular glues with therapeutic effects

Vienna’s Proxygen is taking a ligase-agnostic approach to finding molecular glues with therapeutic effects.

Mar 6, 2021 | 2:34 AM GMT

Austrian newco Proxygen is identifying cancer therapies that act via protein

Read the full 615 word article

How to gain access

Continue reading with a
two-week free trial.